Laboratory monitoring thresholds referenced in this study align with prior evidence and expert consensus: in Nivolumab-associated hepatotoxicity, the risk of severe injury markedly increases when ALT or AST remain above five times the normal upper limit (44); in Cetuximab-related hypomagnesemia, magnesium concentrations below 0.4 mmol/L often correlate with severe clinical manifestations (45). Here, GPT is linked to familial primary hypomagnesemia.